论文部分内容阅读
Objective To investigate the quantitation of hepatitis B e antigen(HBeAg)at week 24 in predicting the efficacy of pegylated-interferon alfa-2a(Peg-IFN-α2a)in HBeAg-positive chronic hepatitis B(CHB)patients at week 48 and to find a useful predictor for treatment efficacy and investigate individualized treatment of antiviral therapy.Methods Ninety-six HBeAg-positive CHB patients with detectable HBeAg who were treated with Peg-IFN-α2a were enrolled in this trial.They were categorized into 3 groups according to the changes of HBeAg in week
Objective To investigate the quantitation of hepatitis B e antigen (HBeAg) at week 24 in predicting the efficacy of pegylated-interferon alfa-2a (Peg-IFN-α2a) in HBeAg-positive chronic hepatitis B (CHB) patients at week 48 and to find a useful predictor for treatment efficacy and investigate individualized treatment of antiviral therapy. Methods Ninety-six HBeAg-positive CHB patients with detectable HBeAg who were treated with Peg-IFN-α2a were enrolled in this trial. The were were categorized into 3 groups according to the changes of HBeAg in week